Abstract Background: Ciprofloxacin is administered for treating urinary tract infections (UTIs); alas, increasing problems in treatment are rooted in rising resistance rates, especially in older patients and according to the used dosage. Objectives: In particular concerning age and dose of ciprofloxacin, to assess how such factors influence resistance in UTI patients and to evaluate the risk factors responsible for ciprofloxacin resistance. Methods: Ninety UTI patients who took Ciprofloxacin were observed in this study. Gender, ethnicity, age, history of antibiotic administration, and existing antibiotic resistance were the independent variables tested. Infection rates of resistance were computed against the aged group and the type of UTI. The impacts of dosage on the development of drug resistance and regrowth of colonies were distinct too. Results: In the research, the ciprofloxacin resistance level was below 53.3 %, while it was found that the resistance was gentler to uncomplicated UTIs than complicated ones (36.4%). Almost two-thirds of the patients aged more than 50 years suffered from bacterial resistance (71.4%). An increase in dose from 500 mg to 750 mg of cisplatin gave an initial response rate above 95% but a 76% resistance rate developed and colony regrowth of 90% over the 500 mg group regrowth of 80%. There were also risk factors that appeared to relate to drug resistance most notably age over 50 years, complicated UTI, frequent use of ciprofloxacin, and history of ESBL-producing infection. Conclusion: Elderly individuals and those with complicated UTIs are at higher risk for ciprofloxacin resistance. The study suggests careful antibiotic consideration in this population and the eventual repositioning of the tools to control resistant infections. More research is needed to understand these resistance methods and recommend measures for the use of antibiotics while treating UTIs.